More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved PTC's ...

PTC India Financial Services Ltd., incorporated in the year 2006, is a Small Cap company (having a market cap of Rs 2,201.75 Crore) operating in Term Lending Institutions sector. PTC India Financial ...

In a potentially pivotal trial, PTC Therapeutics' experimental therapy for Huntington's disease (HD) met its primary endpoint, but questions about the data have raised doubts about the company's ...

It has been about a month since the last earnings report for PTC Inc. (PTC). Shares have added about 2.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...

I've upgraded PTC Inc. to a Buy at ~$179 per share after strong FQ4 2025 results, robust customer contract growth, and improved shareholder returns. PTC's focus on product lifecycle management, ...

Constant Currency ARR Growth: 8.5% year-over-year. Free Cash Flow Growth: 16% year-over-year, totaling $857 million for fiscal '25. Revenue Contribution from Kepware and ThingWorx: Approximately $200 ...

PTC is selling off its IoT businesses, Kepware and ThingWorx, in order to hone its focus on SaaS and AI, according to CEO Neil Barua, as the conglomerate announced a sale of the operations to asset ...

Goldman Sachs flags PTC Industries as a key APAC pick driven by titanium and aerospace growth catalysts. Goldman Sachs has added PTC Industries in its latest APAC Conviction List. The global brokerge ...

PTC Inc. (NASDAQ:PTC) reported its financial results for the third quarter of 2025, showcasing strong growth in annual recurring revenue (ARR) and notable advancements in AI-driven product innovation.

Shares of PTC Industries rallied 5 per cent to ₹17,900 on the BSE in Monday’s intra-day trade after the company said it received a Purchase Order from Gas Turbine Research Establishment (GTRE), ...